PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $164 million in its first quarter.
The Palo Alto, California-based company said it had a loss of 84 cents per share.
The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share.
The rare disease drug developer posted revenue of $194.5 million in the period, which topped Street forecasts. Eight analysts surveyed by Zacks expected $179.8 million.
BridgeBio Pharma shares have decreased 12% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $67.58, a climb of 89% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
